ctr6 Antibody

What is CCR6 and why is it significant as an antibody target?

CCR6 is a G protein-coupled receptor (GPCR) family member that plays a fundamental role in immune homeostasis and activation. It is specifically expressed in B lymphocytes, certain subsets of effector and memory T cells, regulatory T cells, and immature dendritic cells, making it a valuable marker for these immune cell populations . CCR6 has only one chemokine ligand, CCL20, and their interaction (the CCR6/CCL20 axis) is implicated in various disease mechanisms including cancer, psoriasis, multiple sclerosis, HIV infection, and rheumatoid arthritis .

The CCR6/CCL20 pathway is particularly significant because it plays a crucial role in recruiting pro-inflammatory cells to local tissues. Th17 cells expressing CCR6 produce inflammatory cytokines including IL-17, IL-21, and IL-22, which contribute to inflammatory responses . Given its involvement in multiple disease pathways and specific expression pattern, CCR6 represents an attractive target for both diagnostic and therapeutic antibody development.

How are monoclonal antibodies against CCR6 generated?

Researchers employ several methods to develop monoclonal antibodies against CCR6, with two primary approaches being cell immunization and peptide immunization:

Cell Immunization Method:
This approach involves immunizing animals (often mice) with cells overexpressing the target receptor. For example, researchers have generated anti-CCR6 antibodies by:

• Transfecting the L1.2 cell line (murine pre-B cell lymphoma) with human CCR6 or CXCR3 genes using expression vectors

• Selecting transfectants with high expression levels

• Immunizing C57BL/6 mice intraperitoneally with the transfected cells multiple times

• Administering a final intravenous immunization

• Removing the spleen and fusing cells with the SP2/0 cell line to generate hybridomas

Peptide Immunization Method:
An alternative approach uses synthetic peptides representing specific regions of CCR6:

• Synthesizing peptides corresponding to specific segments of CCR6 (often the N-terminal region)

• Conjugating these peptides to carrier proteins like KLH (Keyhole Limpet Hemocyanin)

• Immunizing animals with these conjugated peptides

• Screening the resulting antibodies for specific binding to CCR6

For example, C₆Mab-13, a rat IgG₁ monoclonal antibody against mouse CCR6, was developed using the peptide immunization method targeting the N-terminal peptide sequence .

What techniques can be used to verify CCR6 antibody specificity?

Confirming antibody specificity is crucial for reliable research outcomes. Several complementary methods are commonly employed:

Flow Cytometry:
Anti-CCR6 antibodies can be tested against:

• CCR6-overexpressing cell lines (e.g., transfected CHO-K1 cells)

• Cell lines endogenously expressing CCR6 (e.g., P388 mouse lymphoid neoplasma cells, J774-1 mouse macrophage-like cells)

• Primary cells known to express CCR6 (e.g., certain T cell subsets)

Flow cytometry provides information about antibody binding to native CCR6 in its cellular context and allows quantification of binding to different cell populations.

Enzyme-Linked Immunosorbent Assay (ELISA):
ELISA can be used to:

• Test antibody binding to purified CCR6 protein or peptides

• Evaluate cross-reactivity with related proteins

• Perform epitope mapping using peptide arrays or mutated peptides

Surface Plasmon Resonance (SPR):
SPR analysis provides quantitative measurements of antibody-antigen interactions:

• Determination of binding kinetics (association and dissociation rates)

• Calculation of dissociation constants (KD) to quantify binding affinity

• For example, C₆Mab-13 was found to have a KD of 2.8 × 10⁻⁹ M for CHO/mCCR6 cells, indicating high-affinity binding

Functional Assays:
These assays assess whether the antibody can inhibit CCR6 function:

• Cell migration assays in response to CCL20

• Signaling assays measuring downstream effectors of CCR6 activation

• Antibody-dependent cellular cytotoxicity (ADCC) assays

How can epitope mapping be performed for anti-CCR6 antibodies?

Epitope mapping is essential for understanding antibody function and optimizing antibody design. For CCR6 antibodies, several complementary approaches can be employed:

Alanine Scanning Mutagenesis:
This systematic approach identifies critical residues for antibody binding:

• Generate a series of peptides with single alanine substitutions spanning the suspected epitope region

• Test antibody binding to each mutant peptide using ELISA

• Identify positions where alanine substitution abolishes or significantly reduces antibody binding

For example, researchers mapped the epitope of C₆Mab-13 (anti-mouse CCR6) using this approach:

• A panel of 20 alanine-substituted peptides covering amino acids 1-20 of mouse CCR6 was tested

• The D11A mutation completely abolished antibody binding, identifying Asp11 as a critical residue

• This was further confirmed by SPR analysis, which showed that G9A and D11A mutations prevented binding

Surface Plasmon Resonance Analysis:
SPR can provide quantitative insights into the effects of mutations:

• Immobilize wild-type and mutant peptides or proteins on sensor chips

• Measure antibody binding kinetics to each variant

• Calculate binding affinities (KD) to quantify the impact of each mutation

In the case of C₆Mab-13, SPR analysis revealed that both Gly9 and Asp11 were critical for antibody binding, as KD values could not be calculated for G9A and D11A mutants due to lack of binding .

X-ray Crystallography and Cryo-EM:
For high-resolution epitope mapping:

• Form complexes between the antibody (or Fab fragment) and CCR6 (or peptide)

• Determine the three-dimensional structure using X-ray crystallography or cryo-electron microscopy

• Identify contact residues and structural features of the epitope

These approaches can reveal not only the specific amino acids involved but also the conformational aspects of the epitope.

What are the challenges in developing CCR6-targeting therapeutics and how do antibodies compare to small molecules?

The development of CCR6-targeting therapeutics faces several challenges, with distinct considerations for antibody-based versus small molecule approaches:

Challenges in Small Molecule Development:

• Screening difficulties: GPCRs like CCR6 are challenging targets for small molecule screening due to their complex structure and membrane localization

• Selectivity issues: Achieving selectivity among chemokine receptors, which share structural similarities, can be difficult with small molecules

• Access to binding pockets: Many small molecules target binding pockets that may be deep within the transmembrane domains of GPCRs

Advantages of Antibody-Based Approaches:

• High specificity: Antibodies can achieve exquisite specificity for CCR6 over other chemokine receptors

• Access to extracellular domains: Antibodies can target the extracellular N-terminal domain and loops of CCR6, which are more accessible than transmembrane regions

• Effector functions: Antibodies retain immunological effector functions like antibody-dependent cellular cytotoxicity (ADCC), which can be advantageous for certain therapeutic applications

• Extended half-life: The intact Fc region in antibody formats provides for extended serum half-life compared to small molecules

Innovative Antibody Formats:
To enhance therapeutic potential, researchers are developing specialized antibody formats:

• Bispecific antibodies: These can simultaneously target CCR6 and another relevant receptor (e.g., CXCR3), allowing for more precise targeting of specific cell populations. For example, researchers have developed a fully humanized, tetravalent bispecific antibody composed of a complete IgG1 with a C-terminal stabilized single-chain Fv that binds both CXCR3 and CCR6

• Antibody-drug conjugates (ADCs): While not specifically mentioned for CCR6 in the search results, the CD6-ADC approach described could be adapted for CCR6. This strategy involves conjugating cytotoxic payloads to antibodies for selective delivery to target cells

Currently, there are no approved drugs against CCR6, highlighting the need for continued research in this area .

How can researchers evaluate the functional effects of anti-CCR6 antibodies?

Assessing the functional impact of anti-CCR6 antibodies is crucial for understanding their potential therapeutic applications. Several methodologies can be employed:

Cell Migration Assays:
Since the CCR6/CCL20 axis regulates immune cell trafficking, migration assays are particularly relevant:

• Transwell migration assays: Measure the migration of CCR6-expressing cells toward CCL20 in the presence or absence of anti-CCR6 antibodies

• 3D migration assays: Evaluate cell movement through extracellular matrix components to better mimic in vivo conditions

• Live cell imaging: Track cell movement in real-time to assess migration patterns and velocities

For example, researchers demonstrated that a bispecific antibody targeting CXCR3 and CCR6 could potently inhibit immune cell migration, providing evidence for its functional activity .

Signaling Pathway Analysis:
CCR6 activation triggers intracellular signaling cascades that can be monitored:

• Calcium flux assays: Measure intracellular calcium mobilization following CCL20 stimulation

• Phosphorylation studies: Assess the phosphorylation of downstream signaling molecules using Western blotting or phospho-flow cytometry

• Reporter assays: Use cells expressing pathway-specific reporters to monitor CCR6-dependent signaling

Immune Cell Functional Assays:
Since CCR6 is expressed on immune cells, evaluating immunological functions is important:

• Cytokine production: Measure the production of inflammatory cytokines (IL-17, IL-21, IL-22) by CCR6+ Th17 cells in the presence of anti-CCR6 antibodies

• T cell proliferation assays: Assess the impact on T cell activation and proliferation

• Antibody-dependent cellular cytotoxicity (ADCC): Determine whether the antibody can induce ADCC against CCR6-expressing target cells

The bispecific antibody targeting CXCR3 and CCR6 was shown to induce specific ADCC, demonstrating its ability to not only block receptor function but also potentially eliminate target cells .

In Vivo Disease Models:
To evaluate therapeutic potential, researchers can test anti-CCR6 antibodies in relevant disease models:

• Autoimmune disease models: Such as experimental autoimmune encephalomyelitis (multiple sclerosis model), psoriasis models, or rheumatoid arthritis models

• Cancer models: Particularly for cancers where CCR6 plays a role in tumor progression or metastasis

• Inflammatory disease models: Including inflammatory bowel disease models

These assays can be adapted to test various antibody formats, including conventional monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates.

What considerations are important when developing bispecific antibodies targeting CCR6?

Bispecific antibodies (BsAbs) targeting CCR6 offer unique advantages for precise immune cell targeting but require careful design considerations:

Target Selection and Biological Rationale:

• Complementary target identification: Select a second target that works synergistically with CCR6 targeting. For example, CXCR3 was paired with CCR6 to target Th1, Th17, or pathogenic Th17.1 cells that express either or both receptors

• Cell specificity profile: Analyze the expression pattern of both targets to ensure the bispecific antibody will selectively target the desired cell populations

• Pathway interactions: Consider how the signaling pathways of both targets interact and whether dual blockade provides additive or synergistic effects

Format Selection:
Various BsAb formats exist, each with advantages and limitations:

• IgG-scFv fusion: The example in the search results used a fully humanized, tetravalent BsAb composed of a complete IgG1 with a C-terminal stabilized single-chain Fv (scFv). This format preserves the intact Fc region, maintaining ADCC functionality and extended serum half-life

• Alternative formats: Other possibilities include dual-variable domain immunoglobulins (DVD-Igs), diabodies, or tandem scFvs, depending on the specific requirements

Production and Purification:

• Expression system selection: The bispecific antibody targeting CXCR3 and CCR6 was produced using stably transfected Chinese Hamster Ovary (CHO) cells

• Purification strategy: Develop appropriate purification protocols to ensure homogeneity of the final product

• Stability testing: Evaluate thermal and long-term stability of the bispecific format

Functional Validation:
Comprehensive testing should include:

• Binding validation: Verify specific binding to both targets using flow cytometry and SPR as demonstrated for the CXCR3/CCR6 bispecific antibody

• Functional assays: Test whether the bispecific antibody inhibits migration of cells expressing either or both targets

• Effector function assessment: Evaluate ADCC activity against appropriate target cells

• Comparison with monospecific antibodies: Compare the bispecific antibody's performance with that of the individual monospecific antibodies to demonstrate advantages

Preclinical Development:

• Pharmacokinetic studies: Evaluate serum half-life and tissue distribution

• Efficacy testing: Test in relevant disease models where both targets play a role

• Safety assessment: Evaluate potential off-target effects and toxicity

The development of bispecific antibodies targeting CCR6 and complementary receptors represents an innovative approach for treating inflammatory and autoimmune disorders by precisely targeting specific pathogenic T cell subsets.